Toggle main navigation
News
Insights
Meetings
Multimedia
ASCO AI in Oncology
Search
Close
AI in Oncology
Bladder Cancer
Breast Cancer
Cardio-oncology
CNS Cancers
Colorectal Cancer
Cost of Care
Infectious Diseases
Gastrointestinal Cancer
Genomics/Genetics
Geriatric Oncology
Global Cancer Care
Gynecologic Cancers
Head and Neck Cancer
Health-Care Policy
Hepatobiliary Cancer
Immunotherapy
Kidney Cancer
Leukemia
Lung Cancer
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Neuroendocrine Tumors
Pancreatic Cancer
Prostate Cancer
Sarcoma
Skin Cancer
Survivorship
Thyroid Cancer
Solid Tumors
Hematologic Malignancies
Issues in Oncology
Lung Cancer
Advertisement
The ASCO Post
Lung Cancer
Lung Cancer
FDA Grants Accelerated Approval to Neladalkib for
ALK
-Positive NSCLC
November 17
2 min read
Today, neladalkib (Nelkarmi), a kinase inhibitor, was granted accelerated approval for adults with previously treated, locally advanced or metastatic
ALK
-positive non–small cell lung cancer (NSCLC).
Lung Cancer
Surgical Resection Associated With Lower Mortality Than SABR in Early-Stage NSCLC
November 13
3 min read
Lung Cancer
KEYNOTE-867: Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
November 11
2 min read
Lung Cancer
Claudia Henschke, PhD, MD: Finding Lung Cancer in Time
November 10
9 min read
Lung Cancer
First-Line T-DXd: A Change of DESTINY for HER2-Mutant NSCLC?
November 10
12 min read
Lung Cancer
Beyond Chemotherapy: Overall Survival Nearly Doubled With Investigational Immunotherapy in Advanced Squamous NSCLC
November 10
10 min read
Lung Cancer
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
November 6
2 min read
Latest in Lung Cancer
Load More
Advertisement